235 related articles for article (PubMed ID: 34972706)
21. The frequency of mutations in advanced thyroid cancer in Japan: a single-center study.
Toda S; Iwasaki H; Okubo Y; Hayashi H; Kadoya M; Takahashi H; Yokose T; Hiroshima Y; Masudo K
Endocr J; 2024 Jan; 71(1):31-37. PubMed ID: 38044137
[TBL] [Abstract][Full Text] [Related]
22. Poorly differentiated thyroid carcinoma of childhood and adolescence: a distinct entity characterized by DICER1 mutations.
Chernock RD; Rivera B; Borrelli N; Hill DA; Fahiminiya S; Shah T; Chong AS; Aqil B; Mehrad M; Giordano TJ; Sheridan R; Rutter MM; Dehner LP; Foulkes WD; Nikiforov YE
Mod Pathol; 2020 Jul; 33(7):1264-1274. PubMed ID: 31937902
[TBL] [Abstract][Full Text] [Related]
23. Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma.
Sandulache VC; Williams MD; Lai SY; Lu C; William WN; Busaidy NL; Cote GJ; Singh RR; Luthra R; Cabanillas ME
Thyroid; 2017 Jan; 27(1):81-87. PubMed ID: 27785980
[TBL] [Abstract][Full Text] [Related]
24. Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes.
Bikas A; Ahmadi S; Pappa T; Marqusee E; Wong K; Nehs MA; Cho NL; Haase J; Doherty GM; Sehgal K; Barletta JA; Alexander EK; Landa I
Clin Cancer Res; 2023 Jul; 29(14):2678-2685. PubMed ID: 37260297
[TBL] [Abstract][Full Text] [Related]
25. Novel Recurrent Altered Genes in Chinese Patients With Anaplastic Thyroid Cancer.
Zhang L; Ren Z; Su Z; Liu Y; Yang T; Cao M; Jiang Y; Tang Y; Chen H; Zhang W; Gong R; Wei T; Peng Y; Liu B; Zhang W; Yang L; Hu Y; Li Z; Zhu J; Xu H; Shu Y; Luo H
J Clin Endocrinol Metab; 2021 Mar; 106(4):988-998. PubMed ID: 33428730
[TBL] [Abstract][Full Text] [Related]
26. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
Qin Y; Wang JR; Wang Y; Iyer P; Cote GJ; Busaidy NL; Dadu R; Zafereo M; Williams MD; Ferrarotto R; Gunn GB; Wei P; Patel K; Hofmann MC; Cabanillas ME
Thyroid; 2021 Aug; 31(8):1235-1243. PubMed ID: 33599171
[No Abstract] [Full Text] [Related]
27. TERT promoter mutations in thyroid cancer.
Liu R; Xing M
Endocr Relat Cancer; 2016 Mar; 23(3):R143-55. PubMed ID: 26733501
[TBL] [Abstract][Full Text] [Related]
28. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
Song YS; Lim JA; Choi H; Won JK; Moon JH; Cho SW; Lee KE; Park YJ; Yi KH; Park DJ; Seo JS
Cancer; 2016 May; 122(9):1370-9. PubMed ID: 26969876
[TBL] [Abstract][Full Text] [Related]
29.
Camargo Barros-Filho M; Barreto Menezes de Lima L; Bisarro Dos Reis M; Bette Homem de Mello J; Moraes Beltrami C; Lopes Pinto CA; Kowalski LP; Rogatto SR
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884810
[TBL] [Abstract][Full Text] [Related]
30. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O
Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032
[TBL] [Abstract][Full Text] [Related]
31. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
[TBL] [Abstract][Full Text] [Related]
32. [
Yang T; Chen C; Pan NF; Sun LY; Jiang XL; Li JN; Tang Y; Jiang Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 50(6):919-924. PubMed ID: 31880125
[TBL] [Abstract][Full Text] [Related]
33. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M; Yan C; Xiao J; Wang T; Ling R
Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
[TBL] [Abstract][Full Text] [Related]
34. Genomic Characterization of Differentiated Thyroid Carcinoma.
Song YS; Park YJ
Endocrinol Metab (Seoul); 2019 Mar; 34(1):1-10. PubMed ID: 30912334
[TBL] [Abstract][Full Text] [Related]
35. Mechanistic Insights of Thyroid Cancer Progression.
Leandro-García LJ; Landa I
Endocrinology; 2023 Aug; 164(9):. PubMed ID: 37503738
[TBL] [Abstract][Full Text] [Related]
36. Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma.
Wang JR; Montierth M; Xu L; Goswami M; Zhao X; Cote G; Wang W; Iyer P; Dadu R; Busaidy NL; Lai SY; Gross ND; Ferrarotto R; Lu C; Gunn GB; Williams MD; Routbort M; Zafereo ME; Cabanillas ME
JCO Precis Oncol; 2022 Aug; 6():e2100504. PubMed ID: 35977347
[TBL] [Abstract][Full Text] [Related]
37. Molecular Pathology of Poorly Differentiated and Anaplastic Thyroid Cancer: What Do Pathologists Need to Know?
Volante M; Lam AK; Papotti M; Tallini G
Endocr Pathol; 2021 Mar; 32(1):63-76. PubMed ID: 33543394
[TBL] [Abstract][Full Text] [Related]
38. Mouse Models as a Tool for Understanding Progression in Braf
Landa I; Knauf JA
Endocrinol Metab (Seoul); 2019 Mar; 34(1):11-22. PubMed ID: 30784243
[TBL] [Abstract][Full Text] [Related]
39. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.
Ballester LY; Sarabia SF; Sayeed H; Patel N; Baalwa J; Athanassaki I; Hernandez JA; Fang E; Quintanilla NM; Roy A; López-Terrada DH
Pediatr Dev Pathol; 2016; 19(2):94-100. PubMed ID: 26366474
[TBL] [Abstract][Full Text] [Related]
40. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer.
Yoo SK; Song YS; Lee EK; Hwang J; Kim HH; Jung G; Kim YA; Kim SJ; Cho SW; Won JK; Chung EJ; Shin JY; Lee KE; Kim JI; Park YJ; Seo JS
Nat Commun; 2019 Jun; 10(1):2764. PubMed ID: 31235699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
